Phase II clinical trial of JVS-100 for critical limb ischaemia authorised in the USA


Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announced on 3 January 2011 that the FDA authorised commencement of a phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischaemia. 

JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1), which has been shown in several pre-clinical studies to promote tissue repair through activation of natural stem cell repair pathways, promotion of new blood vessel formation and prevention of on-going cell death. The new trial builds on the JVS-100 cardiovascular programme that includes a US phase I heart failure  clinical trial for which the company recently completed enrolment of 17 patients.

The randomised, placebo-controlled study will evaluate the efficacy and safety of JVS-100 in 48 patients (36 JVS-100 treated; 12 placebo) with Rutherford class IV or V critical limb ischaemia.  The clinical trial will measure several efficacy endpoints including time to amputation, transcutaneous oximetry (TcPO2), ankle-brachial index (ABI) and ulcer closure. 


“Critical limb ischaemia is a devastating disease for which there is currently no FDA-approved drug for treatment,” said Douglas Losordo, principal investigator for the trial and director of the Feinberg Cardiovascular Research Institute at the Northwestern University Feinberg School of Medicine. “Novel regenerative therapies, such as JVS-100, have the potential to restore blood flow and improve outcomes for these patients.”


The Juventas therapeutic platform is based on discoveries made nearly a decade ago by Marc Penn, director of the Bakken Heart-Brain Institute at the Cleveland Clinic and Juventas’ chief medical officer. Penn demonstrated that SDF-1 is a strong chemo-attractant for haematopoietic stem cells, with the potential to promote cardiac repair when delivered to the heart hours to months following a heart attack. These findings were published in 2003 in The Lancet and have now been validated by several independent laboratories. The SDF-1 repair pathway is conserved in most end organ systems, including the heart, peripheral vasculature, kidney, skin, liver and eye.


“Our work on SDF-1 originates from the hypothesis that we all have a natural stem cell based repair process that attempts to repair organs following injury,” said Penn. “We believed that if we could identify the molecular factors that activate this pathway, they could be delivered at a time post-injury to promote tissue preservation. SDF-1 has proven to be a key player in driving repair and we are excited to see our findings translating to the clinic with the potential to help patients.”